Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -4.22% and -57.21%, respectively, for the quarter ended February 2026. Do the numbers hold clues to what lies ahead for the stock?